Biocompatible medical device visible in x-ray and method for manufacturing thereof
11738121 · 2023-08-29
Assignee
Inventors
Cpc classification
A61L31/088
HUMAN NECESSITIES
A61L29/18
HUMAN NECESSITIES
A61L31/18
HUMAN NECESSITIES
A61L2400/18
HUMAN NECESSITIES
International classification
A61L29/18
HUMAN NECESSITIES
A61L31/18
HUMAN NECESSITIES
Abstract
A biocompatible medical device is provided having at least one surface, wherein at least a part of this surface is coated with a biocompatible layer configured to provide visibility of the device in X-rays.
Claims
1. A medical device configured as a stent, an intravenous injection tube or a catheter, having at least one surface, wherein at least a part of said surface is coated with a biocompatible layer configured to provide visibility of said device in X-rays, wherein the biocompatible layer comprises at least one metal oxide, the metal oxide being a heavy metal oxide selected from the group consisting of HfO.sub.2, WO.sub.3, and tantalum oxide, and additionally the biocompatible layer comprises a tungsten carbide, and a metal nitride, selected from the group comprising hafnium nitride, tungsten nitride and tantalum nitride, wherein said tungsten carbide, hafnium nitride, tungsten nitride and tantalum nitride are deposited using plasma-enhanced ALD, wherein said biocompatible layer is an Atomic Layer Deposition (ALD) layer.
2. A method for manufacturing a medical device configured as a stent, an intravenous injection tube or a catheter, comprising: obtaining a medical device, having at least one surface; and depositing a biocompatible layer on at least a part of the surface of said device by Atomic Layer Deposition (ALD), wherein said biocompatible layer is configured to provide visibility of said device in X-rays, wherein the biocompatible layer comprises at least one metal oxide, the metal oxide being a heavy metal oxide selected from the group consisting of HfO.sub.2, WO.sub.3, and tantalum oxide, and additionally the biocompatible layer comprises a tungsten carbide, and a metal nitride, selected from the group comprising hafnium nitride, tungsten nitride and tantalum nitride, both the metal carbide and metal nitride deposited via plasma-enhanced atomic layer deposition, wherein said biocompatible layer is an Atomic Layer Deposition (ALD) layer.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1) The invention will now be described, by way of example only, with reference to the accompanying drawings, in which:
(2)
DETAILED DESCRIPTION
(3) Detailed embodiments of the present invention are disclosed herein with the reference to accompanying drawing. The same reference characters are used throughout the drawing to refer to same members. Following citations are used for the members:
(4) 100—a medical device;
(5) 1—a body of the medical device;
(6) 2A, 2B—internal- and external surfaces of the medical device, accordingly;
(7) 3A, 3B—apertures at the ends of the medical device;
(8) 4A, 4B—coating at the internal- and external surfaces of the medical device, accordingly.
(9)
(10) The medical device 100, hereafter, a device, comprises a body 1 with at least one surface.
(11) In preferred configurations, the device 100 is a stent or an intravenous injection tube.
(12) In the device, having at least one surface, said surface is deposited, at least in part, with a coating layer 4A, 4B. The layer is preferably a biocompatible layer configured to provide visibility of said device in X-rays. The biocompatible coating layer is preferably configured as a film, preferably, a thin film having thickness of about and or more than 50 nm.
(13) The coating layer 4A, 4B is applied with a method of chemical deposition in gaseous (vapour) phase, such as Atomic Layer Deposition (ALD) or, alternatively, Chemical Vapour Deposition (CVD). For the purposes of the present disclosure, ALD is utilized as a preferred deposition method.
(14) The basics of an ALD growth mechanism are known to a skilled person. ALD is a special chemical deposition method based on the sequential introduction of at least two reactive precursor species to at least one substrate. It is to be understood, however, that one of these reactive precursors can be substituted by energy when using, for example, photon-enhanced ALD or plasma-assisted ALD, for example PEALD, leading to single precursor ALD processes. For example, deposition of a pure element, such as metal, requires only one precursor. Binary compounds, such as oxides can be created with one precursor chemical when the precursor chemical contains both of the elements of the binary material to be deposited. Thin films grown by ALD are dense, pinhole free and have uniform thickness.
(15) The at least one substrate is typically exposed to temporally separated precursor pulses in a reaction vessel to deposit material on the substrate surfaces by sequential self-saturating surface reactions. In the context of this application, the term ALD comprises all applicable ALD based techniques and any equivalent or closely related technologies, such as, for example the following ALD sub-types: MLD (Molecular Layer Deposition), plasma-assisted ALD, for example PEALD (Plasma Enhanced Atomic Layer Deposition) and photon-enhanced Atomic Layer Deposition (known also as photo-ALD or flash enhanced ALD). The process can also be an etching process, one example of which being an ALE process. It should be noted that with PEALD and photon-enhanced ALD, the additive treatment can be limited to the surfaces visible to the radiation source.
(16) ALD is based on alternating self-saturative surface reactions, wherein different reactants (precursors) provided as chemical compounds or elements in a nonreactive (inert) gaseous carrier are sequentially pulsed into a reaction space accommodating a substrate. Deposition of a reactant is followed by purging the substrate by inert gas. Conventional ALD deposition cycle proceeds in two half-reactions (pulse A-purge A; pulse B-purge B), whereby a (sub)layer of material is formed in a self-limiting (self-saturating) manner, typically being 0.05-0.2 nm thick. Typical substrate exposure time for each precursor ranges within 0.01-1 seconds.
(17) Pulse A comprises a first precursor in a gaseous phase (first precursor vapour) and pulse B comprises a second precursor in a gaseous phase (second precursor vapour). Inactive gas and a vacuum pump are typically used for purging gaseous reaction by-products and the residual reactant molecules from the reaction space during purge A and purge B. A deposition sequence comprises at least one deposition cycle. Deposition cycles are repeated until the deposition sequence has produced a thin film or coating of desired thickness. Deposition cycles can also be either simpler or more complex. For example, the cycles can include three or more reactant vapour pulses separated by purging steps, or certain purge steps can be omitted. On the other hand, photo-enhanced ALD has a variety of options, such as only one active precursor, with various options for purging. All these deposition cycles form a timed deposition sequence that is controlled by a logic unit or a microprocessor.
(18) With reference back to
(19) The body 1 is further coated, at least partly, with said biocompatible coating provided as a single layer or as a number of layers. In embodiments, biocompatible coating is provided on an outer side and/or on an inner side of the device (the body). The biocompatible coating is configured to provide visibility (of coated parts) in X-rays.
(20) The biocompatible layer can comprises at least one metal oxide. In embodiment, the biocompatible layer comprises at least one heavy metal oxide.
(21) In present disclosure, by “heavy metal” we refer to metal elements heavier than selenium (Se); as in terms of atomic weight. Said (heavy) metal oxide layer comprises one or more compound(s) selected from the group consisting of HfO.sub.2 and TaO.sub.x. Thickness of the layer can be selected such, as to provide desired visibility of the device in X-rays. Thicker coating (e.g. 100 nm) provides a clearer image due to attenuation of X-rays after penetration into the coating layer (a film). A part of X-rays is absorbed and a detector is used to capture the change of energy attenuation and reflect such a change with grey scale.
(22) The biocompatible coating layer is preferably provided as an Atomic Layer Deposition (ALD) layer.
(23) The invention further pertains to a method for providing a medical device 100. The method comprises: obtaining a medical device, having at least one surface; and depositing a biocompatible layer on at least a part of the surface of said device by Atomic Layer Deposition (ALD), wherein said biocompatible layer is configured to provide visibility of said device in X-rays.
(24) Deposition of said biocompatible layer is preferably conducted at relatively low temperature, e.g. the temperature below 150° C.
(25) ALD is advantageously utilized hereby to deposit, inter alia, metals, metal oxides and metal carbides, wherein a metal compound can be provided as any one disclosed hereinabove. Additionally, such metals as ruthenium (Ru), platinum (Pt) and palladium (Pd), can be utilized. However, metal oxides can be deposited at low temperatures (less than 100° C.); thus enabling deposition on plastic parts.
(26) A technical effect achieved by the present disclosure is provision of a biocompatible medical device, which is visible in X-rays.
(27) It shall be appreciated by those skilled in the art that the embodiments set forth in the present disclosure may be adapted and combined as desired. The disclosure is thus intended to encompass any possible modifications of the device and the deposition method, recognizable by those of ordinary skill in the art, within a scope of appended claims.